Dosage research on BPC-157

Preclinical research dose ranges

In published preclinical research on BPC-157, administered dose ranges in rodent models have spanned several orders of magnitude. The most-cited rodent studies have used doses in the 1 to 10 microgram per kilogram range delivered intraperitoneally or intragastrically, with some studies extending to 10 nanograms per kilogram at the low end and to 10 milligrams per kilogram at the high end. The specific dose chosen in any given study reflects the model system, the endpoint being measured, and the route of administration.

The tendon-ligament-bone interface literature (rodent Achilles tendon transection and medial collateral ligament repair models) most commonly reports doses in the 10 microgram per kilogram range delivered intraperitoneally over multi-day or multi-week protocols. The gastric protection literature (NSAID co-administration, ethanol-induced gastric injury, and ulcer models) has used a similar dose range, often delivered intragastrically rather than intraperitoneally. The peripheral nerve crush literature has reported similar microgram-per-kilogram dose levels in rats and mice.

The vascular and microcirculatory endpoints described in the published mechanistic work (Sikiric and colleagues, and others) have used doses across the same approximate range, with the VEGFR2-Akt-eNOS signalling characterisation most often demonstrated at the 10 microgram per kilogram dose level in rats. The brain-gut axis literature uses similar doses with the route of administration reflecting whether the endpoint is central or peripheral.

Dose-response considerations from the published literature

The published BPC-157 literature has not converged on a single canonical dose-response curve because the model systems and endpoints vary widely. What the literature has reported is that effects are generally observed across a broad range of doses (the so-called “flat dose-response” pattern), with investigators reporting similar qualitative effects at 1 microgram per kilogram and at 10 milligrams per kilogram in some tissue systems. This pattern is unusual relative to many pharmaceutical compounds and is a feature investigators have noted in the published reviews.

Different routes of administration have not produced uniformly different dose-response patterns in the published rodent work. Investigators have reported similar effects from intraperitoneal, intragastric, and topical administration in matched models, though the absolute dose levels needed to achieve a given effect differ by route. The pharmacokinetic literature reports a short circulating half-life with functional effects persisting beyond what the half-life alone would predict, consistent with downstream-signalling-cascade activation rather than a direct receptor-occupancy mechanism.

Investigators publishing in the BPC-157 field have noted that no rigorous Phase 1 dose-ranging trial in human subjects has appeared in the indexed clinical-trial literature at the time of writing. The interstitial cystitis pilot report (Sikiric et al., 2024) used 500 micrograms sublingually twice daily over an eight-week observation window in a small open-label patient series; that study is a clinical-pilot report rather than a Phase 1 dose-ranging trial, and the dose level reflects the investigators’ protocol design rather than an established human dose-finding curve.

Reconstitution math and per-vial dose calculation

A 10 mg lyophilised BPC-157 vial reconstituted with 2 mL of bacteriostatic water yields a stock concentration of 5 mg per mL, which is the most common stock concentration in published rodent protocols using BPC-157 from research-grade lyophilised vials. From this stock, a research aliquot of 0.1 mL contains 500 micrograms of BPC-157; an aliquot of 0.02 mL contains 100 micrograms. Researchers working in microgram-per-kilogram dose ranges in rodent in-vivo experiments typically further dilute the stock to a working concentration appropriate to the model. The reconstituted aliquot is refrigerated at 2-8 degrees Celsius, protected from light, and standard peptide-handling practice in the published literature reports stability of the reconstituted material across the experimental observation window when these storage conditions are maintained.

Research-protocol design considerations

Protocol-design choices in the published BPC-157 literature reflect several recurring considerations. Dose selection tends to anchor at the 10 microgram per kilogram range in rodent in-vivo work because that level is well-characterised across the most-cited studies and produces measurable effects across multiple tissue systems in the published record. Investigators designing a new rodent study often begin at that anchor and add comparator arms at higher and lower doses to characterise the dose-response curve in their specific model.

Route of administration in the published rodent work is chosen to match the endpoint: intragastric administration is common for gastric-mucosa and gut endpoints; intraperitoneal administration is common for systemic endpoints; subcutaneous administration appears in studies designed to mimic the delivery route used in any future human investigation. Topical and intra-articular administration appear in a smaller subset of the literature focused on local tissue endpoints.

Multi-day and multi-week protocols are more common than single-dose protocols in the regeneration literature, reflecting the time scale over which tissue remodeling endpoints are measured. Acute single-dose protocols appear in the pharmacokinetic and signalling-cascade literature where the endpoint is measured within hours of dosing. The published handling literature on BPC-157 reports stability of the reconstituted material across these observation windows under standard refrigerated storage conditions.

References

1. Krivic A et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Orthopaedic Research, 2011. [PMID 21030672]
2. Sikiric P et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Current Pharmaceutical Design, 2014. [PMID 23755725]
3. Sikiric P et al. BPC 157 and blood vessels. Current Pharmaceutical Design, 2014. [PMID 23782145]
4. Hsieh MJ et al. Therapeutic potential of pro-angiogenic BPC-157 is associated with VEGFR2 activation and upregulation. Journal of Molecular Medicine, 2017. [PMID 27847966]
5. Chang CH et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Frontiers in Pharmacology, 2019. [PMID 30915550]
6. Sikiric P et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 2021. [PMID 34267654]
7. Seiwerth S et al. The stable gastric pentadecapeptide BPC 157 pleiotropic beneficial activity and its possible mechanisms. Pharmaceutics, 2024. [PMID 38675421]
8. Sikiric P et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Cureus, 2024. [PMID 39325560]
9. Seiwerth S et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Pharmaceuticals, 2025. [PMID 40789979]